Haifeng M. Wu MD

Haifeng M. Wu MD
Assoc ProfessorCollege of Medicinewu.395@osu.edu
185A Hamilton Hall 1645 Neil Avenue Columbus Ohio 43210
Phone:614-293-9873Fax: 614-292-3144
  • Experimental Therapeutics

General Research Interest

Presently, I am applying the technological platform of SELDI-TOF to develop assays for enhancement of personalized cancer care. Specifically, utilizing one technological platform to set up clinical assays in the areas of: 1) genotyping the single nucleotide polymorphisms (SNPs) for guiding cancer care and for prediction of clinical outcomes (theranostics). The known SNPs that influence drug efficacy and drug toxicity such as CYP2D6, DPD/IVS14+1G>A, UGT1A1 will be the primary candidates in this undertaking; 2) rapid and cost-effective monitoring of plasma drug levels such as 5-FU to improve clinical efficacy and drug safety in cancer care and chemoprevention.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu